Solitomab

N/A

Report date: 2026/03/19 16:46:30

Base Information

Drug NameSolitomab

Drug Alias NameAnti-CD3 anti-EpCAM bispecific antibody - AmgenMT110 monoclonal antibodySolitumomabMT-110AMG-110

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-chain FV antibody fragment (scFv)Biologics > T cell engagers

Mechanisms of ActionCD3 T-cell engagersEpithelial cell adhesion molecule inhibitors

TargetsT cell surface glycoprotein CD3Epithelial cell adhesion molecule

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryGermany

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMicromet Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesAmgen Research (Munich) Gmbh

Active IndicationsN/A

Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A